175 related articles for article (PubMed ID: 33195345)
1. Corticosteroids Improve Renal Survival: A Retrospective Analysis From Chinese Patients With Early-Stage IgA Nephropathy.
Qin A; Pei G; Tang Y; Tan L; Wei X; Zhong Z; Zhou L; Chen C; Qin W
Front Med (Lausanne); 2020; 7():585859. PubMed ID: 33195345
[No Abstract] [Full Text] [Related]
2. Combined Immunosuppressive Treatment May Improve Short-Term Renal Outcomes in Chinese Patients with Advanced IgA Nephropathy.
Tan L; Tang Y; Peng W; Mathew BS; Qin W
Kidney Blood Press Res; 2018; 43(4):1333-1343. PubMed ID: 30099439
[TBL] [Abstract][Full Text] [Related]
3. Corticosteroids or immunosuppressants were not superior to supportive care in IgA nephropathy patients with mild proteinuria.
Pei G; Tan J; Tang Y; Tan L; Zhong Z; Zhou L; Chen C; Qin W
Medicine (Baltimore); 2020 Jun; 99(24):e20513. PubMed ID: 32541473
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroids could improve the renal outcome of IgA nephropathy with moderate proteinuria.
Zhong Z; Tang Y; Tan J; Tan L; Pei G; Qin W
Int Urol Nephrol; 2021 Jan; 53(1):121-127. PubMed ID: 32944888
[TBL] [Abstract][Full Text] [Related]
5. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.
Ma F; Yang X; Zhou M; Bai M; Zhao L; Li L; Dong R; Liu C; Li R; Sun S
J Nephrol; 2020 Dec; 33(6):1241-1250. PubMed ID: 32447619
[TBL] [Abstract][Full Text] [Related]
6. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of corticosteroids in immunoglobulin A nephropathy with less than 25% crescents.
Chen J; Xu H; Peng Z; Lin L; Li C; Zhu X; Liu S
Clin Exp Nephrol; 2020 Jan; 24(1):73-81. PubMed ID: 31605314
[TBL] [Abstract][Full Text] [Related]
8. Long-term renal survival and undetected risk factors of IgA nephropathy in Chinese children-a retrospective 1243 cases analysis from single centre experience.
Wu H; Fang X; Xia Z; Gao C; Peng Y; Li X; Zhang P; Kuang Q; Wang R; Wang M
J Nephrol; 2020 Dec; 33(6):1263-1273. PubMed ID: 32507961
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis.
Liu T; Wang Y; Mao H; Yang L; Zhan Y
Medicine (Baltimore); 2021 Feb; 100(8):e24541. PubMed ID: 33663060
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive therapy versus supportive care in IgA nephropathy patients with stage 3 and 4 chronic kidney disease.
Ștefan G; Stancu S; Zugravu A; Petre N; Secăreanu S; Popa O; Capusa C
Medicine (Baltimore); 2022 Sep; 101(36):e30422. PubMed ID: 36086774
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy With Stage 3 or 4 CKD: A Retrospective Cohort Study.
Zhao J; Ma F; Bai M; Sun S
Clin Ther; 2021 May; 43(5):859-870. PubMed ID: 33863547
[TBL] [Abstract][Full Text] [Related]
13. A validation study of crescents in predicting ESRD in patients with IgA nephropathy.
Zhang X; Shi S; Ouyang Y; Yang M; Shi M; Pan X; Lv J; Wang Z; Ren H; Shen P; Wang W; Zhang H; Xie J; Chen N
J Transl Med; 2018 May; 16(1):115. PubMed ID: 29724226
[TBL] [Abstract][Full Text] [Related]
14. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.
Sarcina C; Tinelli C; Ferrario F; Pani A; De Silvestri A; Scaini P; Del Vecchio L; Alberghini E; Buzzi L; Baragetti I; Pozzi C
Clin J Am Soc Nephrol; 2016 Jun; 11(6):973-981. PubMed ID: 27129712
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressant Agents as Add-On Therapy Failed to Improve the Outcome of Immunoglobulin A Nephropathy with Crescent Score C1.
Bi X; Yu Y; Zhou S; Zhou Y; Zhao J; Xiong J
Nephron; 2024 May; ():1-14. PubMed ID: 38723614
[TBL] [Abstract][Full Text] [Related]
16. Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.
Rivedal M; Haaskjold YL; Eikrem Ø; Bjørneklett R; Marti HP; Knoop T
BMC Nephrol; 2024 Jan; 25(1):42. PubMed ID: 38287343
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
18. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.
Donadio JV; Bergstralh EJ; Grande JP; Rademcher DM
Nephrol Dial Transplant; 2002 Jul; 17(7):1197-203. PubMed ID: 12105241
[TBL] [Abstract][Full Text] [Related]
19. Renal outcome after tonsillectomy plus corticosteroid pulse therapy in patients with immunoglobulin A nephropathy: results of a multicenter cohort study.
Hoshino J; Fujii T; Usui J; Fujii T; Ohashi K; Takaichi K; Suzuki S; Ubara Y; Yamagata K
Clin Exp Nephrol; 2016 Aug; 20(4):618-627. PubMed ID: 26577676
[TBL] [Abstract][Full Text] [Related]
20. [Effect of serum IgA/C3 and glomerular C3 staining on clinical prognosis in patients with IgA nephropathy].
Pei GQ; Qin AY; Wang SQ; Tan L; Tang Y; Qin W
Zhonghua Yi Xue Za Zhi; 2020 Aug; 100(30):2372-2377. PubMed ID: 32791814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
